Arkolith/Insider Trading/TPTX/Form 4

Partridge Andrew John

EVP & Chief Commercial OfficerTurning Point Therapeutics, Inc. (TPTX) · full profile →Form 4 · filed Feb 11, 2022
Net Selling
Open-Market Buys
$0
Open-Market Sells
$8K
Net Open-Market Flow
-$8K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 9, 2022Sell(S)221$36.30$8K22K
Feb 9, 2022Grant(A)16K—$038K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 9, 2022Grant(A)59K—$059K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-22-008983) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML